Gaucher disease paradigm: from ERAD to comorbidity

Area of Science:

• Biochemistry
• Genetics
• Cell Biology

Background:

• Gaucher disease (GD) results from mutations in the GBA gene, leading to deficient lysosomal acid beta-glucocerebrosidase (GCase) activity and glucosylceramide accumulation.
• Over 280 GBA mutations are linked to GD, with mutant GCase variants exhibiting varied endoplasmic reticulum (ER) retention due to misfolding.
• Misfolded GCase proteins are targeted for ER-associated degradation (ERAD) via proteasomes, a process influencing GD pathogenesis.

Purpose of the Study:

• To review the mechanisms of ER-associated degradation (ERAD) for mutant GCase variants.
• To discuss the implications of ERAD on Gaucher disease severity.
• To explore the consequences for both GD patients and carriers of GBA mutations.

Main Methods:

• Literature review of studies on GBA mutations, GCase protein folding, ERAD pathways, and Gaucher disease.
• Analysis of the relationship between GCase ER retention, proteasomal degradation, and clinical phenotypes.
• Synthesis of current understanding of ERAD's role in GD pathogenesis.

Main Results:

• Mutant GCase variants are prone to ER retention and subsequent ERAD.
• The extent of ER retention and ERAD influences the severity of Gaucher disease.
• ERAD pathways play a critical role in determining the cellular consequences of GBA mutations.

Conclusions:

• ERAD of misfolded GCase is a key factor in Gaucher disease pathology.
• Understanding ERAD mechanisms offers insights into GD variability.
• Targeting ERAD pathways may hold therapeutic potential for Gaucher disease patients and carriers.